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Intratumour injection, commonly used for gene or drug delivery but also associated with needle biopsy or insertion of invasive
measuring devices, may damage tumour microvessels. To examine this possibility, SCCVII tumours grown subcutaneously in
C3H mice were injected with a 26 gauge needle containing 0.1 ml of the ﬂuorescent dye Hoechst 33342 to label cells lining
the track of the needle. Hoechst-labelled cells sorted from these tumours were more sensitive to killing by hypoxic cell
cytotoxins (tirapazamine, RSU-1069) and less sensitive to damage by ionizing radiation. Hoechst-labelled cells also bound the
hypoxia marker pimonidazole when given by i.p. injection. Intratumour injection transiently increased hypoxia from 18 to 70%
in the tumour cells adjacent to the track of the needle. The half-time for return to pre-treatment oxygenation was about
30 min; oxygenation of tumour cells along the track had recovered by 20 h after intratumour injection. This effect could have
signiﬁcant implications for intratumour injection of drugs, cytokines or vectors that are affected by the oxygenation status of
the tumour cells as well as potential effects on biodistribution via local microvasculature.
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Intratumour injection is used to deliver a variety of agents, includ-
ing drugs, genes and cytokines that are available in limited
amounts or that do not normally localize to tumours (Graeber et
al, 1999; Nemunaitis et al, 1999). Delivering chemotherapy drugs
directly to tumours should produce a higher drug concentration
in the tumour than in neighbouring normal tissues (Amano et
al, 1988). However, one of the concerns of intratumour injection
is that inhomogeneities in drug delivery within the tumour may
result in failure to adequately expose all of the tumour cells to
the agent (McDouall and Evelhoch, 1990).
Therefore, experiments (reported here) were designed initially to
measure the distribution of drugs given by intratumour injection.
The bioreductive hypoxic cell cytotoxin tirapazamine was injected
together with a rapidly bound ﬂuorescent dye, Hoechst 33342,
directly into SCCVII murine tumours. Hoechst 33342 binds to cells
lining the track of the needle, but tirapazamine was expected to
diffuse to hypoxic regions within the tumours. Interestingly,
tumour cells most sensitive to tirapazamine were those cells that
bound the most Hoechst 33342. This led us to question whether
intratumour injection, and presumably other invasive procedures,
may affect local tumour oxygenation.
Our previous efforts to demonstrate an effect of intratumour
needle puncture on average tumour oxygenation in experimental
tumours were inconclusive (Aquino-Parsons et al, 1999). Although
heterogeneity in hypoxic fraction was increased in tumours that
underwent puncture with an Eppendorf oxygen electrode (tip
dimension 250 microns), there was no signiﬁcant change in
median tumour oxygenation 24 h after tumour puncture when
measured using the alkaline comet assay to detect hypoxic cells.
However, the inability to detect signiﬁcant changes in oxygenation
was complicated by intertumour variability in oxygenation and by
the possibility that only those cells adjacent to the needle track
might be affected by the procedure.
To examine the hypoxic status of cells along the needle track, we
used the ﬂuorescent dye Hoechst 33342 in combination with the
hypoxic cell marker pimonidazole to measure the duration and
extent of hypoxia. The importance of Hoechst drug dose and injec-
tion volume were also examined as possible contributors to
hypoxia.
MATERIALS AND METHODS
SCCVII tumours and bioreductive drugs
All procedures were approved by the Animal Care Committee at
the University of British Columbia, and mice were maintained in
a holding facility approved by the Canadian Council on Animal
Care. All procedures conform in every way to the UKCCR Guide-
lines (UKCCR, 1998). SCCVII squamous cell carcinoma cells (Suit
et al, 1985), originally obtained from Dr M Horsman, were trans-
planted subcutaneously over the sacral region of inbred male C3H/
HeN mice, approximately 30 gm in weight. Tumours were used for
experimentation 2–4 weeks later when they had reached a weight
of approximately 400–500 mg. Tirapazamine and RSU-1069 were
kindly provided by Sanoﬁ-Winthrop and by Parke-Davis Pharma-
ceuticals respectively. Tirapazamine was dissolved in phosphate
buffered saline (PBS) and RSU-1069 was dissolved in PBS, pH 4,
immediately before use.
Pimonidazole binding to identify hypoxic cells
To detect hypoxic cells in tumours, mice were injected
intraperitoneally with 100 mg kg
71 pimonidazole hydrochloride
(Hypoxyprobe-1, NPI Inc., Belmont, MA, USA) from a stock solu-
tion containing 20 mg ml
71 in sterile PBS. In one experiment,
pimonidazole was injected i.t. at a dose of 2–50 mg kg
71. Ninety
minutes after intraperitoneal injection of pimonidazole, corre-
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s
Received 23 July 2001; revised 11 October 2001; accepted 1 November
2001
*Correspondence: Dr PL Olive; E-mail: polive@bccancer.bc.ca
British Journal of Cancer (2002) 86, 429–435
ã 2002 The Cancer Research Campaign All rights reserved 0007–0920/02 $25.00
www.bjcancer.comsponding to three plasma half-lives for this drug (Walton et al,
1989), mice were sacriﬁced. Tumours were excised and a single cell
suspension was prepared by mincing in ice-cold PBS and incubat-
ing for 30 min at 378C with a mixture of trypsin, collagenase and
DNase as described previously (Olive, 1989). Cells were then
ﬁltered through 30 mm nylon mesh, centrifuged and resuspended
in cold PBS. Cells were ﬁxed in 70% ethanol and refrigerated over-
night or up to several days before analysis of pimonidazole
binding.
Intratumour injection of Hoechst 33342 and cell sorting
SCCVII tumours were injected using a 26 gauge needle passed
through the overlying skin into the tumour. The angle of injection
was changed to create three tracks through the tumour using the
same entry site, and typically 0.1 ml Hoechst 33342 dissolved in
PBS was slowly injected. Single cells were prepared using the
enzyme disaggregation method, and cells were incubated with
ﬂuorescein-isothiocyanate conjugated anti-mouse IgG to discrimi-
nate tumour cells from macrophages (Olive, 1989). Cells were
sorted on the basis of the Hoechst concentration gradient, as
previously described. Sorted cells were analyzed for pimonidazole
binding, or for cell viability using a standard clonogenicity assay.
The plating efﬁciency of cells from untreated SCCVII tumours
was 0.3–0.4.
Flow cytometry analysis of pimonidazole binding
Ethanol-ﬁxed cells were centrifuged, washed once in PBS then
resuspended in PST (PBS containing 4% serum and 0.1% Triton
X-100). A FITC-conjugated (1:1000 dilution) primary antibody
was added to 2610
6 alcohol-ﬁxed cells for 2 h at 378C (for anti-
body source and description, see Raleigh et al, 1999). Samples
were rinsed in PST and those cells that were incubated with
the unconjugated primary were resuspended in a FITC conju-
gated secondary antibody diluted 1:100 in PST for 1 h at
378C. Samples were rinsed in PST and resuspended for DNA
staining in 1 ml PBS containing 1 mgm l
71 4,6-diamidino-2-
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Figure 1 SCCVII tumours (400–500 mg) were injected with 20 ng
Hoechst 33342 in 0.1 ml along three tracks within the tumour. Tumours
were removed at the times indicated, and a single cell suspension was pre-
pared for analysis using a Becton-Dickinson FACS 440 cell sorter. The solid
circles indicate the distribution of 1600 ng Hoechst 33342 given by a single
i.v. injection.
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Figure 2 SCCVII tumours were injected with 0.1 ml PBS containing 0.1 mg tirapazamine and 0.1 mg Hoechst 33342. Sixty minutes later, tumours were
excised and a single cell suspension was prepared. Cell sorting was used to select cells on the basis of Hoechst 33342 ﬂuorescence so that fraction 10 outo f
10 in (A) or six out of six in (H) represent the most ﬂuorescent fraction of cells within the tumour (i.e., the cells closest to the needle track). (A) Shows the
mean and standard deviation for clonogenic survival for three tumours injected with 0.1 mg tirapazamine. (H) Shows the average tail moment for (B–G)
that indicate the wide heterogeneity in DNA damage within individual cells of the six sort fractions.
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a Coulter Epics Elite cell sorter (Beckman Coulter Corp. Hialeah,
FL, USA).
Univariate histograms, plotted as cell number vs logarithm of
ﬂuorescence anti-pimonidazole antibody intensity, were analyzed
by a least-squares approach for three normal curves representing
aerobic, intermediate and hypoxic tumour cell populations. The
hypoxic fraction was deﬁned as the percentage of the population
that bound, on average, 10 times more pimonidazole than the
aerobic population of cells (Olive et al, 2000). Since the SCCVII
tumour is tetraploid, any normal cells with diploid DNA content
were easily eliminated from analysis.
Image analysis of pimonidazole binding
To examine co-localization of Hoechst 33342 and pimonidazole in
frozen sections, SCCVII tumours were embedded in OCT
compound and frozen sections (approximately 7 micron diameter)
were prepared using a cryostat. Sections were examined immedi-
ately with UV excitation using a Zeiss axioplan epi-ﬂuorescence
microscope with CCD camera and image software. Areas that
showed signiﬁcant Hoechst 33342 ﬂuorescence (especially longitu-
dinal sections of blood vessels) were captured. Then sections were
ﬁxed in 70% ethanol (Hoechst 33342 is lost at this step) and
stained for pimonidazole using the FITC-conjugated anti-pimoni-
dazole monoclonal antibody (1:1000 dilution in PST). The same
area of the tumour was re-examined using 488 nm excitation. Digi-
tized images were pseudo-coloured and superimposed using
Picture Publisher software.
Analysis of DNA damage and hypoxic fraction using the
comet assay
DNA single-strand breaks produced by tirapazamine were
measured using the alkaline comet assay as previously described
(Olive, 1995). DNA damage was quantiﬁed as an increase in tail
moment, an indicator of damage that is proportional to the
number of strand breaks per cell (Olive et al, 1990). Tail moment
is deﬁned as the product of the per cent of DNA (ﬂuorescence) in
the tail and the distance between the means of the head and tail
ﬂuorescence distributions.
RESULTS
Figure 1 shows the distribution of Hoechst 33342 when injected
into SCCVII tumours via a 26 gauge needle (400 micron diameter)
inserted through the skin overlying the subcutaneous tumour with
three slow passes through the tumour from the same entry site. A
total of 0.1 ml Hoechst 33342 (20 ng) was delivered. When
tumours were injected with 0.1 ml PBS or with 0.1 ml PBS
containing 20 ng Hoechst 33342, the overall hypoxic fraction was
not signiﬁcantly different (18.6+12.1 vs 20.8+7.4, mean and stan-
dard deviation, n=6). Five minutes to 24 h later, tumours were
excised, and a single cell suspension was prepared. Single cells were
then analyzed by ﬂow cytometry. Fluorescence within the fractions
from an individual tumour varied 20–40-fold when tumour cells
were assigned to 10 equal fractions. Fluorescence intensity
increased dramatically in fractions 9 and 10, representing 10–
20% of the tumour cells.
Intensity decreased slightly over the ﬁrst 2 h following intra-
tumour injection but was 4–5 times lower by 24 h after injection.
Intravenous injection of 80 times more Hoechst 33342 (1.6 mg per
mouse) produced a similar average intensity but a reduced maxi-
mum intensity (black circles) consistent with a larger percentage
of tumour cells being exposed to the dye when delivered by intra-
venous injection.
The distribution of DNA damage within SCCVII tumours after
intratumour injection of tirapazamine together with Hoechst 33342
is shown in Figure 2. Cells were selected by ﬂuorescence activated
cell sorting based on the gradient of Hoechst 33342 ﬂuorescence
intensity, with the expectation that the brightly ﬂuorescent cells
would be those cells closest to the site of injection. Sorted popula-
tions were subsequently analyzed for DNA damage using the
alkaline comet assay, and for cell survival using a clonogenicity
endpoint. Cells that contained the most Hoechst 33342 also
showed the most killing and DNA damage by tirapazamine. Similar
results were obtained using another bioreductive drug that also
preferentially kills hypoxic cells, RSU-1069 (data not shown).
Since the drug concentration was highest in cells along the track
of the needle, one could argue that more damage occurred here
simply because these cells were exposed to the highest drug dose.
Therefore, response to ionizing radiation, which produces three
times more killing in aerobic than hypoxic cells, was also used to
determine whether cells bordering the needle track were hypoxic.
Tumours that had been injected with Hoechst 5 min before expo-
sure to radiation showed less killing of the brightly ﬂuorescent cells
compared to the dimmest cells (Figure 3), supporting the idea that
cells next to the site of injection were hypoxic. This protective
effect decreased with time after injection, indicating either a return
of oxygen to these cells or perhaps their loss. As expected, the aver-
age response of the population was not signiﬁcantly different than
the response of the dimmest population.
To directly conﬁrm that cells lining the needle track after intra-
tumour injection were hypoxic, the hypoxia marker pimonidazole
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Figure 3 Effect of ionizing radiation on survival of cells lining the needle
track. Tumours were injected with 20 ng Hoechst 33342 in 0.1 ml. Five
minutes to 20 h later, tumours were exposed to 10 Gy X-rays and subse-
quently excised. Single cells were sorted based on Hoechst 33342 concen-
tration into six fractions and plated for colony formation. The relative
clonogenic survival of the brightest cells compared to the dimmest cells
of the tumour is plotted as a function of time of irradiation after Hoechst
injection. The mean and standard deviation for ﬁve tumours is shown. Note
that when Hoechst 33342 is given by i.t. injection after irradiation (~),
there is no distinction between the sensitivity of the dimmest and brightest
cells. ** Indicate values signiﬁcantly different from the response when irra-
diation is given post-injection.
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cells were also sorted on the basis of the Hoechst 33342 concentra-
tion gradient, and sorted cells were ﬁxed and subsequently analyzed
for pimonidazole binding using anti-pimonidazole antibodies.
Regardless of the concentration of pimonidazole injected into the
tumour, the brightly ﬂuorescent cells showed 60–70% hypoxic
cells while the dimly ﬂuorescent cells contained only 3–11%
hypoxic cells (Figure 4).
Delivering pimonidazole i.p. at various times before and after
intratumour injection of Hoechst 33342 provided more convincing
evidence that cells lining the needle track were hypoxic. Figure 5
shows three digitized images of frozen sections of tumours given
an i.p. injection of pimonidazole followed 5 min later by i.t. injec-
tion of Hoechst 33342. Regions of tumours labelled with Hoechst
33342 were identiﬁed and imaged. Then after ﬁxation and incuba-
tion with anti-pimonidazole antibody, the same regions were
imaged again. Superimposed images indicate clear co-localization
of pimonidazole and Hoechst 33342.
To quantify this effect, pimonidazole was administered i.p. at
various times before and after i.t. injection of Hoechst 33342.
Single cells from these tumours were sorted on the basis of Hoechst
33342 concentration into populations representing the brightest
one out of six of the tumour cells and the dimmest one out of
six of the cells. These sorted populations were then analyzed for
pimonidazole adducts. When pimonidazole was injected 90 min
or more before intratumour injection of Hoechst, there was no
signiﬁcant difference between the hypoxic fraction of the Hoechst
brightest or dimmest cells, that is, the hypoxic fraction was similar
for cells lining the track of the needle or distant from the track
(Figure 6). This result is expected since the plasma half-life of
pimonidazole in mice is only about 30 min so most of the pimo-
nidazole will have already bound to existing hypoxic cells before
the Hoechst was administered. When pimonidazole was given i.p.
30 min or less before Hoechst 33342 injection, then there was sufﬁ-
cient plasma pimonidazole to bind to any regions of hypoxia
created by the intratumour injection. In fact, when administered
within 5 min of each other, the hypoxic fraction of the Hoechst
brightest cells increased to almost 70%. For at least 30 min follow-
ing intratumour injection, the hypoxic fraction remained
signiﬁcantly elevated. Pooled values from 1 to 4 h were signiﬁ-
cantly elevated in the brightest cells compared to the dimmest
population when analyzed using a paired t-test. By 20 h after intra-
tumour injection, hypoxic fraction in the cells lining the needle
track returned to normal levels (Figure 6).
Hoechst 33342 is known to be vasoactive at high concentrations
(Trotter et al, 1990), so intratumour injection of this drug could
lead to a localized decrease in blood ﬂow and might explain the
hypoxia associated with the injection site. Alternatively, injection
of a signiﬁcant volume of ﬂuid into a tumour could increase inter-
stitial ﬂuid pressure, leading to vascular collapse and a subsequent
increase in hypoxia. To examine these possibilities, different
concentrations and volumes of Hoechst 33342 were injected
5 min after i.p. administration of pimonidazole. Although there
was a trend for the hypoxic fraction to increase with increasing
Hoechst 33342 concentration (Figure 7a), it is unlikely that
Hoechst alone was responsible for the effect observed in Figure
6. A 20-fold variation in ﬂuid volume injected had no apparent
effect on the measured hypoxic fraction when the same amount
(20 ng) or concentration (1 mg ml
71) of Hoechst was injected
(Figure 7b).
DISCUSSION
Intratumour injection is widely used to administer genes, drugs
and cytokines. In this situation, small gauge needles are inserted
along with some volume of ﬂuid, generally in several passes
through the tumour. We found that intratumour injection of the
hypoxic cell speciﬁc cytotoxin tirapazamine produced cell killing
and DNA damage in SCCVII tumour cells closest to the needle
track in spite of our expectation that this drug should be able to
diffuse to hypoxic areas of the tumour (Figure 2). This led us to
examine whether local regions of hypoxia might be produced by
intratumour injection. Results using ionizing radiation and pimo-
nidazole as methods to detect hypoxic cells conﬁrmed that cells
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Figure 4 SCCVII tumours were injected in three tracks with 0.1 ml PBS containing 0.1 mg Hoechst 33342 and either 2, 10 or 50 mg kg
71 pimonidazole.
Tumours were removed 90 min later. Although the average antibody intensity within the tumours increased six-fold over this dose range, the percentageo f
cells that bound 10 times more pimonidazole than the ‘aerobic’ population of cells was similar. (A) Shows the percentage of hypoxic cells for each sort
fraction. (B–G) Show ﬂow histograms and curve ﬁtting for pimonidazole antibody-stained cells sorted from the 2 mg kg
71 tumour. The distribution
for the hypoxic cells (indicated in black) is shown for the six sort fractions from the dimmest Hoechst-stained cells (B) to the brightest Hoechst-stained
cells (G).
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hypoxic than cells distant from the injection sites.
The effects we have observed here are conﬁned to the immediate
region of cells surrounding the sites of injection. This observation
is consistent with previous studies that found only a small region
of the RIF-1 tumour surrounding the site of D2O injection was
actually labelled with this tracer as measured using NMR imaging
(McDouall and Evelhoch, 1990). In these studies, RIF-1 tumours
were injected with 0.1 ml D2O and the label could not be detected
after about 10 min. Higher volumes (0.4 ml) labelled a larger area
of the tumour but were cleared at the same rate. This suggests that
the slower recovery kinetics observed in this study is more likely to
represent repair of damage to microvessels rather than clearance of
the injected ﬂuid. Jain and colleagues also noted that using a very
slow infusion rate from a single point source, bulk ﬂow was
responsible for removal of ﬂuid and reabsorption via blood vessels
was minimal in the LS174T xenograft tumour (Boucher et al,
1998). Although the authors suggested that stagnant blood ﬂow
in the center of these tumours might be responsible, this result
could also be explained if blood vessels were damaged in the region
surrounding the infusion needle.
The typical hypoxic fraction in the SCCVII tumour of air-
breathing mice is about 12% when measured using pimonidazole
binding (Olive et al, 2000). However, 5 min following intratumour
injection, this increased to 18–20%. This is consistent with
expected results if 10% of the cells of the tumour are made hypoxic
by the passage of the needle three times through this tumour
volume. Since we were using a potentially vasoactive dye, Hoechst
33342, to delineate the cells bordering the needle track, we could
not rigorously exclude the possibility that this ﬂuorescent drug
was responsible for producing vasoconstriction and hypoxia where
the concentration was greatest. However, we did not observe signif-
icant changes in hypoxic fraction along the track when the Hoechst
concentration was varied over 10-fold. The time course studies
shown in Figures 3 and 6 indicate that the local hypoxia produced
by intratumour injection is maximum within the ﬁrst few minutes
after injection and that recovery occurred quite rapidly over the
ﬁrst 30 min then continued gradually over the next several hours.
Although loss of Hoechst 33342-labelled cells might explain this
recovery, Hoechst 33342 intensity in the brightest populations
remained high for the ﬁrst few hours after intratumour injection
(Figure 1), arguing against signiﬁcant cell loss.
Localized damage to the tumour blood vessels caused by inva-
sive procedures is not unexpected. Previous reports have
indicated that invasive techniques, such as ﬁne needle aspiration
biopsy, can occasionally produce extensive tissue damage (e.g.
Gordon et al, 1993; Lee et al, 1994). Insertion of needle electrodes
is also part of invasive procedures including measurements of pH
or oxygen, measurement of interstitial ﬂuid pressure and laser
Doppler measurements of tumour blood ﬂow. These procedures
differ from intratumour injections in that no ﬂuid is administered.
Moreover, the Eppendorf oxygen electrode continuously advances
through the tissue making it unlikely that any damage by the elec-
trode will contribute to the measurements. Needle size is also likely
to be important, and the tip of the Eppendorf oxygen electrode
tapers to about 250 microns (compared to 400 microns for a 26
gauge needle). Also, as the tip of the oxygen electrode is relatively
blunt compared to a needle, there should be less damage to the
microvessels. The question of oxygen electrode damage to tumours
has been addressed previously (Steinberg et al, 1995). These
authors examined tissue destruction along the needle tracks, noting
microvessel rupture and destroyed sinusoids. They concluded that
local oxygen tension measurements should be completed quickly
and performed only in previously undamaged regions of the
tumour. Microelectrode damage was also found to be largely
conﬁned to the tissue track at puncture sites in arteries (Cole et
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Figure 5 Three digitized images of frozen sections of SCCVII tumours
injected i.t. with Hoechst 33342 5 min after i.p. injection of 100 mg kg
71
pimonidazole. The blue-stained nuclei indicate the regions that stained with
Hoechst 33342. The green stained cells bound FITC-conjugated anti-pimo-
nidazole antibodies. The remaining black background shows unstained re-
gions of the tumours.
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Figure 6 Relation between time of intratumour injection and increase in
binding of pimonidazole in SCCVII tumours. Mice were given i.t. injections
with Hoechst 33342 at time ‘0’. Pimonidazole (100 mg kg
71) was injected
i.p. 4 h before to 20 h after i.t. injection of Hoechst. Ninety minutes after
pimonidazole injection, tumours were excised and single cells were sorted
into six fractions on the basis of Hoechst concentration. Sorted samples
were analyzed for the percentage of hypoxic cells in the Hoechst dimmest
one out of six and brightest one out of six of the tumour cells. The means
and standard deviations for 3–6 tumours per time point are shown.
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of passing an Eppendorf electrode four times through the SCCVII
tumour on hypoxic fraction measured using the comet assay
(Aquino-Parsons et al, 1999). No signiﬁcant change in average
tumour oxygenation was observed 5 min after tumour puncture.
In the same study, the calculated hypoxic fraction from clonogenic
measurements was also found to be the same for control tumours
and tumours that were punctured with an Eppendorf electrode
5 min before irradiation. These results are consistent with the idea
that immediate changes in tumour oxygenation are conﬁned largely
to the region of cells adjacent to the needle track. Since only a few
per cent of the tumour cells are affected, this difference is unlikely
to be detected in heterogeneous animal tumour models when only
average responses are measured.
The fact that adjacent tumour cells are hypoxic and gradually
reoxygenate has implications for the use of intratumour injection
to deliver drugs. Biodistribution of agents delivered by this route
is likely to be affected by damage to tumour microvessels. In addi-
tion, oxygen dependency for toxicity has been demonstrated for
ionizing radiation, cytokines and several anticancer drugs (for a
review, see Hockel and Vaupel, 2001). The hypoxic microenviron-
ment could explain why photodynamic therapy was not improved
by intratumour injection of haematoporphyrin in spite of increas-
ing the drug concentration compared to i.p. administration (Lin et
al, 1988). Toxicity of TNF-a is also known to be highly dependent
on tumour cell oxygenation status (Lynch et al, 1995). Hypoxia- or
stress-induced upregulation of genes such as cyclooxygenase-2,
TP53, and inducible nitric oxide synthase, may also inﬂuence the
effect of agents injected directly into tumours.
ACKNOWLEDGEMENTS
This work was supported grant number CA-37879 awarded by the
National Cancer Institute, DHHS. Pimonidazole antibody was
kindly supplied by JA Raleigh (CA-50995). The technical assistance
of Charlene Vikse and Laura Tower is gratefully acknowledged.
REFERENCES
Amano T, Prout GRJ, Lin CW (1988) Intratumour injection as a more effec-
tive means of porphyrin administration for photodynamic therapy. J Urol
139: 392–395
Aquino-Parsons C, Luo C, Vikse CM, Olive PL (1999) Comparison between
the comet assay and the oxygen microelectrode for measurement of
tumour hypoxia. Radiother Oncol 51: 179–185
Boucher Y, Brekken C, Netti PA, Baxter LT, Jain RK (1998) Intratumoural
infusion of ﬂuid: estimation of hydraulic conductivity and implications
for the delivery of therapeutic agents. Br J Cancer 78: 1442–1448
Cole MA, Bernick S, Puffer HW, Warner NE, Crawford DW (1983) Methods
in laboratory investigation. Identiﬁcation and evaluation of histopathology
at microelectrode puncture sites. Lab Invest 49: 626–631
Gordon DL, Gattuso P, Castelli M, Bayer W, Emanuele MA, Brooks MH
(1993) Effect of ﬁne needle aspiration biopsy on the histology of thyroid
neoplasms. Acta Cytol 37: 651–654
Graeber IP, Eshraghi AA, Paiva MB, Paek WH, Castro DJ, Jovanovic S,
Scherer H, Soudant J, Saxton RE (1999) Combined intratumour cisplati-
num injection and Nd:YAG laser therapy. Laryngoscope 109: 447–454
Hockel M, Vaupel P (2001) Tumour hypoxia: deﬁnitions and current clinical,
biologic, and molecular aspects. J Natl Cancer Inst 93: 266–276
Lee KC, Chan JK, Ho LC (1994) Histologic changes in the breast after ﬁne-
needle aspiration. Am J Surg Pathol 18: 1039–1047
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s
%
 
H
y
p
o
x
i
c
 
c
e
l
l
s
60
40
20
0
0.01 0.1 1
Dose Hoechst (µg tumour
–1) Volume Hoechst (ml tumour
–1)
60
40
20
0
0.01 0.1
A. B.
Figure 7 Effect of Hoechst 33342 injection dose and injection volume on hypoxic fraction measured using pimonidazole binding. (A) SCCVII tumours
were injected in three tracks with 0.1 ml containing various amounts of Hoechst 33342 administered 5 min after i.p. injection of 100 mg kg
71 pimonidazole.
The means and standard deviations for 3–5 tumours per dose are shown. (B) SCCVII tumours were injected in three tracks with either the same amount of
Hoechst (20 ng, triangles) or the same concentration of Hoechst (1 mg ml
71, circles) in different volumes of PBS given 5 min after i.p. injection of pimo-
nidazole. Results for individual tumours are shown. The dotted lines indicate the dose and volume used in Figures 3 and 6. Open symbols show the response
of the brightest one out of six of the tumour cells and closed symbols show the response of the dimmest one out of six of the cells.
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